Nucleic acid therapies (NATs) such as triplex-forming oligonucleotides (TFOs) offer innovative cancer treatment options to selectively target amplified oncogenes, such as HER2. However, challenges in intracellular and nuclear delivery hinder their clinical tra... ...
